摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

benzyl 3,4-dihydro-7-nitro-2H-pyrano[3,2-b]pyridin-3-ylcarbamate | 884306-78-9

中文名称
——
中文别名
——
英文名称
benzyl 3,4-dihydro-7-nitro-2H-pyrano[3,2-b]pyridin-3-ylcarbamate
英文别名
benzyl N-(7-nitro-3,4-dihydro-2H-pyrano[3,2-b]pyridin-3-yl)carbamate
benzyl 3,4-dihydro-7-nitro-2H-pyrano[3,2-b]pyridin-3-ylcarbamate化学式
CAS
884306-78-9
化学式
C16H15N3O5
mdl
——
分子量
329.312
InChiKey
HENDPWBULLJDKW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    106
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为反应物:
    描述:
    benzyl 3,4-dihydro-7-nitro-2H-pyrano[3,2-b]pyridin-3-ylcarbamatebenzyl 6,8-dihydro-3-nitro-5H-pyrano[3,4-b]pyridin-5-ylcarbamate氢溴酸丙酰氯三乙胺 在 crude mixture 、 dichloromethane hydrateSodium sulfate-III二氯甲烷盐酸碳酸氢钠丙酮 作用下, 以 二氯甲烷溶剂黄146 为溶剂, 反应 7.5h, 以gave a pure fraction of N-(6,8-dihydro-3-nitro-5H-pyrano[3,4-b]pyridin-5-yl)propionamide (2.2 g, 33% for two steps) as a white solid的产率得到N-(6,8-dihydro-3-nitro-5H-pyrano[3,4-b]pyridin-5-yl)propionamide
    参考文献:
    名称:
    Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
    摘要:
    本发明涉及式I的芳香族化合物,其中Ar是苯基或芳香5-或6-成员C-键杂环基,其中Ar可以携带1个基团Ra,其中Ar还可以携带1或2个基团Rb; X是N或CH; Y是O,S,-CH═N-,-CH═CH-或-N═CH-; A是CH2,O或S; E是CR6R7或NR3; R1是C1-C4-烷基,C3-C4-环烷基,C3-C4-环烷基甲基,C3-C4-烯基,氟化C1-C4-烷基,氟化C3-C4-环烷基,氟化C3-C4-环烷基甲基,氟化C3-C4-烯基,甲酰基或C1-C3-烷基羰基; R1a是H,C2-C4-烷基,C3-C4-环烷基,C3-C4-烯基,氟化C1-C4-烷基,氟化C3-C4-环烷基,或R1a和R2一起是(CH2)n,其中n为2或3,或R1a和R2a一起是(CH2)n,其中n为2或3; R2和R2a彼此独立地为H,CH3,CH2F,CHF2或CF3; R3为H或C1-C4-烷基; R6,R7彼此独立地选自H,C1-C2-烷基和氟化C1-C2-烷基;及其生理耐受的酸加成盐。本发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易受多巴胺D3受体配体治疗的医疗障碍的制药组合物。
    公开号:
    US08969552B2
  • 作为产物:
    参考文献:
    名称:
    微波辅助合成新型(5-硝基吡啶-2-基)烷基和(5-硝基吡啶-3-基)烷基氨基甲酸酯
    摘要:
    在这项研究中提出了一种新颖的方法,以新颖的(5-硝基吡啶-2-基)烷基和(5-硝基吡啶-3-基)烷基氨基甲酸酯结构单元。它们的构造是通过在微波辐射下使N-氨基甲酸酯α-和β-氨基羰基衍生物与1-甲基-3,5-二硝基-2-吡啶酮1缩合而实现的。母体羰基原料性质的明智选择的修饰影响了反应的区域化学结果,并允许有效地获得新型的含氮支架。具有相同形态相似性的化合物已收集到三个在单个结构参数上彼此不同的库中。
    DOI:
    10.1021/jo802439d
点击查看最新优质反应信息

文献信息

  • [EN] ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES AROMATIQUES D'ARYLSULFONYLMETHYLE OU D'ARYLSULFONAMIDE SUBSTITUES PERMETTANT DE TRAITER DES TROUBLES REPONDANT A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
    申请人:ABBOTT GMBH & CO KG
    公开号:WO2006040178A1
    公开(公告)日:2006-04-20
    The present invention relates to aromatic compounds of the formula (I), wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry 1 or 2 radicals Rb; X is N or CH; Y is O, S, -CH=N-, -CH=CH- or -N=CH-; A is CH2i O or S; E is CR6R7 or NR 3; R1 is C1-C4-alkyl, C3-C4-cycloalkyl, C3-C4-cycloalkylmethyl, C3-C4-alkenyl, fluorinated C1-C4-­alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-cycloalkylmethyl, fluorinated C3-C4­-alkenyl, formyl or C,-C3-alkylcarbonyl; R1a is H, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4 -cycloalkyl, or R1a and R2 together are (CH2)n with n being 2 or 3, or R1a and R2a together are (CH2)n with n being 2 or 3; R2 and R2a are independently of each other H, CH3, CH2F, CHF2 or CF3; R3 is H or C1-C4-alkyl; R6, R7 independently of each other are selected from H, C1-C2-alkyl and fluorinated C1-C2-alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
    本发明涉及式(I)的芳香族化合物,其中Ar是苯基或芳香族5-或6-成员C-键合杂芳基,其中Ar可以携带1个基团Ra,Ar也可以携带1个或2个基团Rb;X是N或CH;Y是O、S、-CH=N-、-CH=CH-或-N=CH-;A是 i、O或S;E是CR6R7或NR3;R1是C1-C4-烷基、C3-C4-环烷基、C3-C4-环烷基甲基、C3-C4-烯基、代C1-C4-烷基、代C3-C4-环烷基、代C3-C4-环烷基甲基、代C3-C4-烯基、甲酰基或C,-C3-烷基羰基;R1a是H、C2-C4-烷基、C3-C4-环烷基、C3-C4-烯基、代C1-C4-烷基、代C3-C4-环烷基,或R1a和R2一起是(CH2)n,其中n为2或3,或R1a和R2a一起是( )n,其中n为2或3;R2和R2a彼此独立地是H、CH3、 F、CHF2CF3;R3是H或C1-C4-烷基;R6、R7彼此独立地选自H、C1-C2-烷基和代C1-C2-烷基;以及其生理耐受的酸盐。该发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗对多巴胺D3受体配体敏感的医疗疾病的药物组合物。
  • Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor
    申请人:Drescher Karla
    公开号:US20090012074A1
    公开(公告)日:2009-01-08
    The present invention relates to aromatic compounds of the formula I wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical R a and wherein Ar may also carry 1 or 2 radicals R b ; X is N or CH; Y is O, S, —CH═N—, —CH═CH— or —N═CH—; A is CH 2 , O or S; E is CR 6 R 7 or NR 3 ; R 1 is C 1 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -cycloalkylmethyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, fluorinated C 3 -C 4 -cycloalkylmethyl, fluorinated C 3 -C 4 -alkenyl, formyl or C 1 -C 3 -alkylcarbonyl; R 1a is H, C 2 -C 4 -alkyl, C 3 -C 4 -cycloalkyl, C 3 -C 4 -alkenyl, fluorinated C 1 -C 4 -alkyl, fluorinated C 3 -C 4 -cycloalkyl, or R 1a and R 2 together are (CH 2 ) n with n being 2 or 3, or R 1a and R 2a together are (CH 2 ) n with n being 2 or 3; R 2 and R 2a are independently of each other H, CH 3 , CH 2 F, CHF 2 or CF 3 ; R 3 is H or C 1 -C 4 -alkyl; R 6 , R 7 independently of each other are selected from H, C 1 -C 2 -alkyl and fluorinated C 1 -C 2 -alkyl; and the physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.
    本发明涉及公式I的芳香族化合物,其中Ar是苯基或含有5或6个成员的芳香族C-连接杂环基团,其中Ar可以携带1个基团Ra,也可以携带1或2个基团Rb;X是N或CH;Y是O,S,-CH═N-,-CH═CH-或-N═CH-;A是CH2,O或S;E是CR6R7或NR3;R1是C1-C4烷基,C3-C4环烷基,C3-C4环烷基甲基,C3-C4烯基,代C1-C4烷基,代C3-C4环烷基,代C3-C4环烷基甲基,代C3-C4烯基,甲酰基或C1-C3烷基羰基;R1a是H,C2-C4烷基,C3-C4环烷基,C3-C4烯基,代C1-C4烷基,代C3-C4环烷基,或R1a和R2一起是( )n,其中n为2或3,或R1a和R2a一起是( )n,其中n为2或3;R2和R2a相互独立地是H,CH3, F,CHF2CF3;R3是H或C1-C4烷基;R6,R7相互独立地选择自H,C1-C2烷基和代C1-C2烷基;以及其生理耐受酸盐。本发明还涉及使用公式I的化合物或其药学上可接受的盐制备用于治疗可通过多巴胺D3受体配体治疗的医疗障碍的制药组合物的用途。
  • ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
    申请人:Abbott GmbH & Co. KG
    公开号:EP1812416B1
    公开(公告)日:2013-08-21
  • ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE SUBSTITUTED AROMATIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MADULATION OF THE DOPAMINE D3 RECEPTOR
    申请人:Abbott GmbH & Co. KG
    公开号:EP1812416A1
    公开(公告)日:2007-08-01
  • US8969552B2
    申请人:——
    公开号:US8969552B2
    公开(公告)日:2015-03-03
查看更多

同类化合物

龙胆胺 龙胆定碱 西藏龙胆碱 萤光红BK 苯酰胺,N-(1,5,7,8-四氢-4-羰基-4H-吡喃并[4,3-b]吡啶-3-基)- 秦艽碱丙 秦艽甲素 盐酸伊立替康杂质20 溶剂红197 吡喃联氮基[2,1-c][1,4]苯并噁嗪,1,2,3,4,4a,5-六氢-(9CI) 伊立替康杂质29 α.-D-核-七吡喃糖苷-6-酮糖,甲基3,7-二脱氧-2-O-甲基-4-O-(苯基甲基)- N-(3,4-二氢-2H-吡喃并[3,2-b]吡啶-4-基)-n-甲基甘氨酸 N-(2-(4-甲氧苯基)乙烯基)-吡咯烷-2,5-二酮 8-碘-3,4-二氢-2H-吡喃并[3,2-c]吡啶 7H-噻喃并[2,3-d]嘧啶 7-溴-2H-吡喃并[3,2-b]吡啶 7-氯-3,4-二氢-2H-吡喃并[2,3-B]吡啶 7-乙基-10-羟基喜树碱中间体 7,8-二氢-6H-硫代吡喃并[3,2-d]嘧啶-2,4-二醇 7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-胺 7,8-二氢-2-(甲硫基)-3H-噻喃并[3,2-d]嘧啶-4(6H)-酮 6H-噻喃并[3,2-d]嘧啶 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-甲醛 6-碘-3,4-二氢-2h-吡喃并[3,2-b]吡啶 6-甲基-3,4-二氢吡喃并[4,3-d]吡啶-1-酮 6-溴-2H-吡喃并[2,3-b]吡啶-4(3H)-酮 6-溴-2-苯基-2H-吡喃并[2,3-b]吡啶 6-溴-2-(4-甲基苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-溴-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(4-氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-氯-2-(3,4-二氯苯基)-3,4-二氢-2H-吡喃并[2,3-b]吡啶 6-(4,4,5,5-四甲基-1,3,2-二氧杂硼硼烷-2-基)-3,4-二氢-2H-吡喃[2,3-b]吡啶 6,8-二碘-3,4-二氢-2H-吡喃[3,2-b]吡啶 5H-噻喃并[2,3-d]嘧啶 5-氧杂-10-氮杂三环[6.2.1.04,9]十一碳-1,3,7,9-四烯 5,8-二氢-6H-吡喃并[3,4-b]吡啶 4H-吡喃并[2,3-b]吡啶-4-酮,6-氯-2,3-二氢-2-甲基-,(R)- 4H-吡喃并[2,3-b]吡啶-4-酮 4-羟甲基-3,4-二氢-2H-吡喃[3,2-B]吡啶-4-醇 4-甲基-7-吗啉基-2H-吡喃并[2,3-b]吡啶-2-酮 4-乙基-7,8-二氢-4-羟基-1H-吡喃并[3,4-f]吲嗪-3,6,10(4H)-三酮 4,4',5'-三甲基氮杂补骨脂素 4'-乙基-7',8'-二氢-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3',10'(4′H)-二酮-d5 4'-乙基-7',8'-二氢-4'-羟基-螺[1,3-二氧戊环-2,6'(3'H)-[1H]吡喃并[3,4-f]吲哚嗪]-3′,10′(4′H)-二酮-d5 3-异噻唑甲酰胺,N-(4-氯-7,8-二氢-5H-吡喃并[4,3-b]吡啶-3-基)- 3-(二烯丙基氨基)-7-氧代-7H-苯并吡喃并[3',2':3,4]吡啶并[1,2-a]苯并咪唑-6-甲腈 3-(4-羟苯在)-4H-吡喃[2,3-B]吡啶-4-酮 3,4-二氢-4-亚甲基-(9ci)-2H-吡喃并[3,2-b]吡啶 3,4-二氢-2h-吡喃并[3,2-b]吡啶-8-羧酸